Michael Sundström

Scientific Director

Karolinska Institutet

SGC, Department of Medicine,
Karolinska University Hospital and Karolinska Institutet,
Tomtebodav. 23A,
171 65 Solna,


+46 70 65 44 662

Michael Sundstrom received his PhD from Uppsala, followed by PostDoctoral studies at Karolinska Institute. From 1993-2000 he was at Pharmacia as Director for structure based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). From end of 2011, we was VP Discovery Research at Karolinska Development. He then re-joined the SGC and is since mid-2014 Scientific Director of European Initiatives at SGC.

Current Duties

Michael has three main responsibilities within the SGC; 1) member of the global research leadership team coordinating projects and activities of common interest within the consortium; 2) site head for SGC Karolinska and 3) main scientific focus and responsibility for the SGC Tissue Platforms in Stockholm, Oxford, Toronto and Montreal; working to establish high quality cell-based assays using patient-derived cell systems in inflammation, oncology and neurodegenerative diseases.

The promise and peril of chemical probes.
Arrowsmith CH, Audia JE, Austin C, Baell J, Bennett J, Blagg J, Bountra C, Brennan PE, Brown PJ, Bunnage ME, Buser-Doepner C, Campbell RM, Carter AJ, Cohen P, Copeland RA, Cravatt B, Dahlin JL, Dhanak D, Edwards AM, Frye SV, Gray N, Grimshaw CE, Hepworth D, Howe T, Huber KV, Jin J, Knapp S, Kotz JD, Kruger RG, Lowe D, Mader MM, Marsden B, Mueller-Fahrnow A, Müller S, O'Hagan RC, Overington JP, Owen DR, Rosenberg SH, Roth B, Ross R, Schapira M, Schreiber SL, Shoichet B, Sundström M, Superti-Furga G, Taunton J, Toledo-Sherman L, Walpole C, Walters MA, Willson TM, Workman P, Young RN, Zuercher WJ
Nat. Chem. Biol.. 2015 11(8):536-41. doi: 10.1038/nchembio.1867
PMID: 26196764

Preclinical target validation using patient-derived cells.
Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD, Sundström M, Barker P, Barsyte D, Bengtson MH, Bell C, Bowness P, Boycott KM, Buser-Doepner C, Carpenter CL, Carr AJ, Clark K, Das AM, Dhanak D, Dirks P, Ellis J, Fantin VR, Flores C, Fon EA, Frail DE, Gileadi O, O'Hagan RC, Howe T, Isaac JT, Jabado N, Jakobsson PJ, Klareskog L, Knapp S, Lee WH, Lima-Fernandes E, Lundberg IE, Marshall J, Massirer KB, MacKenzie AE, Maruyama T, Mueller-Fahrnow A, Muthuswamy S, Nanchahal J, O'Brien C, Oppermann U, Ostermann N, Petrecca K, Pollock BG, Poupon V, Prinjha RK, Rosenberg SH, Rouleau G, Skingle M, Slutsky AS, Smith GA, Verhelle D, Widmer H, Young LT
Nat Rev Drug Discov. 2015 14(3):149-50. doi: 10.1038/nrd4565
PMID: 25722227

Recently targeted kinases and their inhibitors-the path to clinical trials.
Knapp, S; Sundström, M;
Current Opinion in Pharmacology. 2014 17:58-63. doi: 10.1016/j.coph.2014.07.015
PMID: 25113945

Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs
Francavilla C, Rigbolt KT, Emdal KB, Carraro G, Vernet E, Bekker-Jensen DB, Streicher W, Wikström M, Sundström M, Bellusci S, Cavallaro U, Blagoev B, Olsen JV.
Mol Cell.. 2013 51(6):707-22. doi: 10.1016/j.molcel.2013.08.002
PMID: 24011590

A secretory system for bacterial production of high-profile protein targets.
Kotzsch A, Vernet E, Hammarström M, Berthelsen J, Weigelt J, Gräslund S, Sundström M
Protein Sci.. 2011 20(3):597-609. doi: 10.1002/pro.593
PMID: 21308845

A pilot project to generate affinity reagents to human proteins.
Uhlen M, Gräslund S, Sundström M
Nat. Methods. 2008 5(10):854-5. doi: 10.1038/nmeth1008-854
PMID: 18825127

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Fedorov, O; Marsden, B; Pogacic, V; Rellos, P; Müller, S; Bullock, AN; Schwaller, J; Sundström, M; Knapp, S;
Proceedings of the National Academy of Sciences. 2007 104:20523-20528. doi: 10.1073/pnas.0708800104
PMID: 18077363

Insights for the development of specific kinase inhibitors by targeted structural genomics.
Fedorov, O; Sundström, M; Marsden, B; Knapp, S;
Drug Discovery Today. 2007 12:365-372. doi: 10.1016/j.drudis.2007.03.006
PMID: 17467572

Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity.
Ng, SS; Kavanagh, KL; McDonough, MA; Butler, D; Pilka, ES; Lienard, BMR; Bray, JE; Savitsky, P; Gileadi, O; von Delft, F; Rose, NR; Offer, J; Scheinost, JC; Borowski, T; Sundstrom, M; Schofield, CJ; Oppermann, U;
Nature. 2007 448:87-91. doi: 10.1038/nature05971
PMID: 17589501

glqxz9283 sfy39587stf02 mnesdcuix8